Characterization of diffusion and duration of action of a new botulinum toxin type A formulation

Toxicon

Volumn 58, Issue 2, 2011, Pages 159-167

  Stone, Hongran F ^a   Zhu, Zhao ^a   Thach, Thai Q D ^a   Ruegg, Curtis L ^a  

^a Revance Therapeutics Inc   (United States)

Author keywords

Animal model; Botox ; Botulinum neurotoxin type A; Diffusion; Muscle paralysis

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; RT 002; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; FEMALE; GASTROCNEMIUS MUSCLE; MALE; MOUSE; MUSCLE FORCE; MUSCLE TWITCH; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RUNNING; RUNNING DISTANCE; TIBIALIS ANTERIOR MUSCLE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; BOTULINUM TOXINS, TYPE A; CHEMISTRY, PHARMACEUTICAL; COSMETIC TECHNIQUES; DELAYED-ACTION PREPARATIONS; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; MUSCLE, SKELETAL; PARALYSIS; RANDOM ALLOCATION; SPASM; TETANY; TISSUE DISTRIBUTION; WEIGHT GAIN;

ANIMALIA; MURINAE; MUS;

EID: 79960339891     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.05.012     Document Type: Article

References (24)

1. Allen D.L., Harrison B.C., Maass A., Bell M.L., Byrnes W.C., Leinwand L.A. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J. Appl. Physiol. 2001, 90:1900-1908.
2. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001, 39(12):1815-1820.
3. Bambrick L.L., Gordon T. Comparison of the effects of botulinum toxin in adult and neonatal rats: neuromuscular blockage and toxicity. Can. J. Physiol. Pharmcol 1989, 67(8):879-882.
4. Blasi J., Chapman E.R., Link E., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365(6442):160-163.
5. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997, 6:S146-S168. (Review).
6. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg muscle & nerve. Muscle & Nerve September 2009, 40(3):374-380.
7. Cheng C.M., Chen J.S., Patel R.P. Unlabeled uses of botulinum toxins: a review, part 1. Am. J. Health Syst. Pharm. 2006, 63(2):145-152. (Review).
8. Cheng C.M., Chen J.S., Patel R.P. Unlabeled uses of botulinum toxins: a review, part 2. Am. J. Health Syst. Pharm. 2006, 63(3):225-232. (Review).
9. de Almeida A.T., De Boulle K. Diffusion characteristics of outline neurotoxin products and their clinical significance in cosmetic applications. J. Cosmet. Laser Ther. 2007, 9(Suppl. 1):17-22. (Review).
10. Dodd S.L., Selsby J., Payne A., Judge A., Dott C. Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 2005, 46(2):196-203.
11. FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed 2009, FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm175013.htm.
12. Flynn T.C. Update on botulinum toxin. Semin. Cutan. Med. Surg. 2007, 26(4):196-202.
13. Foster K.A., Bigalke H., Aoki K.R. Botulinum neurotoxin - from laboratory to bedside. Neurotox Res. 2006, 9(2-3):133-140.
14. Jankovic J. Botulinum toxin in movement disorders. Curr. Opin. Neurol. 1994, 7(4):358-366. (Review).
15. Keller J.E. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006, 139:629-637.
16. Klein A.W., Carruthers A., Fagien S., Lowe N.J. Comparisons among botulinum toxins: an evidence-based review. Plast. Reconstr. Surg. 2008, 121(6):413e-422e.
17. Koman L.A., Smith B.P., Shilt J.S. Cerebral palsy. Lancet 2004, 363(9421):1619-1631. (Review).
18. Luvisetto S., Rossetto O., Montecucco C., Pavone F. Toxicity of botulinum neurotoxins in central nervous system of mice. Toxicon 2003, 41(4):475-481.
19. Lowe N.J. Overview of botulinum neurotoxins. J. Cosmet. Laser Ther. 2007, 9(Suppl. 1):11-16. (Review).
20. Scott A.B., Rosenbaum A., Collins C.C. Pharmacologic weakening of extraocular muscles. Invest. Ophthalmol. 1973, 12(12):924-927.
21. Stone A.V., Ma J., Whitlock P.W., Koman L.A., Smith T.L., Smith B.P., Callahan M.F. Effects of BOTOX® and Neuronox on muscle force generation in mice. J. Orthop. Res. 2007, 25(12):1658-1664.
22. Turner M.J., Kleeberger S.R., Lightfoot J.T. Influence of genetic background on daily running-wheel activity differs with aging. Physiol. Genomics 2005, 22:76-85.
23. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27(11):552-558.
24. Yaraskavitch M., Leonard T., Herzog W. BOTOX® produces functional weakness in non-injected muscles adjacent to the target muscle. J. Biomech. 2008, 41(4):897-902.